Ecallantide

Ecallantide is a 60-residue protein derived by phage display from the first Kunitz domain of human tissue factor pathway inhibitor, engineered for high-affinity, reversible inhibition of plasma kallikrein. In hereditary angioedema, absent or dysfunctional C1 inhibitor lets kallikrein run unchecked, cleaving high-molecular-weight kininogen into bradykinin. Blocking kallikrein prevents bradykinin from being generated at all, which is a step further upstream than icatibant's receptor blockade. It is expressed in Pichia pastoris, and that non-human expression system is the likely driver of its immunogenicity and anaphylaxis risk.

Targets: Plasma kallikrein, Contact activation (kallikrein-kinin) system

• · 30 mg given as three separate 10 mg (1 mL) subcutaneous injections, ideally rotated across abdomen, thigh or upper arm and at least 2 inches apart. May be repeated once within 24 hours. Not approved for self-administration in the US because of the anaphylaxis boxed warning.

Work out your exact syringe units →

• very commonHeadache
• commonNausea
• commonFatigue
• commonInjection-site reaction
• commonAnti-drug antibody formation— Seroconversion is common and correlates with hypersensitivity risk on re-exposure.
• uncommonAnaphylaxis— Boxed warning. Occurred in roughly 3-4 percent of patients, sometimes on the first exposure, and it can be clinically indistinguishable from the angioedema attack being treated.

• Known clinical hypersensitivity to ecallantide - re-exposure risks anaphylaxis.
• Administration anywhere without immediate access to adrenaline and airway management.
• Patient self-administration, which the US label does not permit.

• redundanticatibant — Both abort acute attacks through the same bradykinin pathway; one on-demand agent is used per attack.
• conflictACE inhibitors — ACE inhibitors elevate bradykinin and provoke angioedema; they should be avoided entirely in these patients.
• redundantC1 esterase inhibitor concentrate — Alternative on-demand therapies for the same attack.

• · Direct observation for at least an hour after dosing for signs of anaphylaxis.
• · Attack diary - frequency, trigger, time to relief.
• · Anti-ecallantide antibody status is not routinely measured but hypersensitivity history must be documented before each dose.

FDA-approved prescription drug for acute hereditary angioedema in patients 12 and older, restricted to administration by a healthcare professional. Not approved in the EU.

• Kalbitor (ecallantide) FDA prescribing information with boxed anaphylaxis warning (label)
• Cicardi et al. 2010, EDEMA4 randomised trial of ecallantide (trial)
• Levy et al. 2010, EDEMA3 ecallantide trial (trial)

Ecallantide attacks the same disease as icatibant but one step upstream. Plasma kallikrein is the protease that cleaves high-molecular-weight kininogen to release bradykinin, and in hereditary angioedema the loss of C1-inhibitor removes the brake on kallikrein so bradykinin production runs away. Ecallantide is a potent, selective, reversible inhibitor of plasma kallikrein with a Ki of 25 picomolar, which is an extraordinarily tight inhibition constant. Blocking kallikrein stops bradykinin being made rather than blocking its receptor, so the attack shuts down at the source. The trade-off is structural: to inhibit a protease with picomolar affinity you need a folded protein domain, not a short synthetic peptide, and a 60-residue recombinant protein made in yeast is immunogenic in a way that a decapeptide with five non-natural residues is not. That is the whole clinical story of ecallantide: better placed in the cascade, worse tolerated in the patient. Anaphylaxis occurred in 3.5 percent of 230 patients across the clinical trial database, notably never on first exposure, all with onset within an hour, and all responsive to standard management. There is also a coagulation consequence of inhibiting kallikrein, which sits in the contact activation pathway: intravenous doses at or above 20 mg/m2 prolong the aPTT, roughly twofold at 80 mg IV, returning to normal by four hours.

Anaphylaxis, at about 3.5 percent of treated patients, is what defines this drug's place in therapy. It is not a first-dose reaction, which means the reassurance of an uneventful first treatment is false reassurance; the risk arrives with sensitisation on subsequent exposures. That is why it carries a boxed warning, why it cannot be self-administered, and why it lost the market to icatibant despite arguably better placement in the cascade. The reactions are typical type I hypersensitivity, appear within an hour, and respond to standard management, but they can be indistinguishable from a worsening HAE attack, which is the specific diagnostic trap: a patient developing stridor 20 minutes after ecallantide might be having an anaphylactic reaction to the drug meant to treat the swelling.

• Plasma kallikrein — Ki = 25 pM (label)

  Potent, selective, reversible active-site inhibition. Blocks conversion of high-molecular-weight kininogen to bradykinin, terminating the attack upstream of the receptor.

• Contact activation pathway (factor XIIa / kallikrein amplification loop)

  Off-target consequence rather than an intended one: aPTT prolongation at high intravenous doses, reflecting kallikrein's role in intrinsic coagulation.

• EDEMA3 Phase 3 · n=72 · 2010

  Treatment outcome score at 4 hours after a single 30 mg subcutaneous dose versus placebo. Median treatment outcome score 50.0 with ecallantide. Reported in NEJM.

• EDEMA4 Phase 3 · n=96 · 2010

  Change from baseline in mean symptom complex severity score at 4 hours: -0.8 with ecallantide versus -0.4 with placebo (p=0.01), with treatment outcome score 53.4 versus 8.1 (p=0.003).

• Integrated analysis of EDEMA3 and EDEMA4 (Sheffer 2011) Pooled analysis of two phase 3 trials · n=143 · 2011

  Pooled efficacy and safety across both double-blind trials; 143 unique patients received 168 treated attacks.

Symptom improvement is measurable at 4 hours, which was the primary endpoint in both registration trials, with earlier onset in many patients. Plasma peak is at 2 to 3 hours and the 2-hour half-life means the drug is gone by about 8 hours. Around 1 in 4 attacks in the trial programme required a second dose.

There is no rational stacking here. Ecallantide is on-demand rescue, given by a clinician, with adrenaline and airway equipment in the room. Combining it with icatibant is pharmacologically redundant, since one blocks the enzyme and the other the receptor for the same mediator, and it has never been studied. As with icatibant, ACE inhibitors are effectively contraindicated in the underlying disease because ACE is the main bradykinin-degrading enzyme. Note that ecallantide's aPTT effect can confuse the coagulation picture if a patient is being anticoagulated at the same time.

Against icatibant: better mechanistic placement, comparable efficacy, dramatically worse safety profile, and clinician-administration only. Against C1-inhibitor concentrate: C1-INH restores the missing regulator itself and inhibits kallikrein among other targets, with a much cleaner safety record, at the price of intravenous administration. Against the modern prophylactic kallikrein inhibitors lanadelumab and berotralstat: those target the same enzyme for prevention rather than rescue, and lanadelumab in particular showed that kallikrein inhibition is an excellent strategy when delivered by a molecule that does not provoke anaphylaxis.

Priced per 30 mg dose (three 10 mg vials) and administered in a clinical setting, so the true cost includes the visit. Not a monthly therapy. I did not verify current pricing.

• ?The one-letter sequence is not stated in the label and I did not resolve it from a protein database in this session, so the sequence object is marked unverified; the Kunitz-domain provenance is from the published literature rather than a sequence I confirmed.
• ?Absolute subcutaneous bioavailability and plasma protein binding are not published in the label.
• ?No pharmacokinetic data exist in renal or hepatic impairment, which the label states explicitly.
• ?Whether EDEMA3 is the NEJM paper and EDEMA4 the Annals paper is stated here from the trial names in the titles and abstracts; some secondary sources reverse them.

• Ecallantide for the treatment of acute attacks in hereditary angioedema Cicardi M, Levy RJ, McNeil DL, et al., N Engl J Med, 2010 · PMID 20818887

  The NEJM phase 3 trial (EDEMA3), 72 patients.

• EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema Levy RJ, Lumry WR, McNeil DL, et al., Ann Allergy Asthma Immunol, 2010 · PMID 20568386

  The second registration trial, 96 patients, with the symptom severity numbers quoted above.

• Ecallantide (DX-88) for acute hereditary angioedema attacks: integrated analysis of 2 double-blind, phase 3 studies Sheffer AL, Campion M, Levy RJ, et al., J Allergy Clin Immunol, 2011 · PMID 21481442

  Pooled efficacy across both registration trials.

• Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks Craig TJ, Li HH, Riedl M, et al., J Allergy Clin Immunol Pract, 2015 · PMID 25609335

  The source of the 3.5 percent anaphylaxis rate in 230 patients over 1,045 doses, and of the observation that no reaction occurred on first exposure.

• Ecallantide: its pharmacology, pharmacokinetics, clinical efficacy and tolerability Bernstein JA, Qazi M, Expert Rev Clin Immunol, 2010 · PMID 20383888

  Consolidated pharmacology review.